Lineage Cell Therapeutics Inc
For the period ended Dec 31, 2024. Filed Mar 10, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 10, 2025
LCTX$1.08+5.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, 2024 | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $45,789 | $35,442 |
| Marketable securities | 2,016 | 50 |
| Accounts receivable, net | 638 | 745 |
| Prepaid expenses and other current assets | 2,554 | 2,204 |
| Total current assets | 50,997 | 38,441 |
| NONCURRENT ASSETS | ||
| Property and equipment, net | 2,251 | 2,245 |
| Operating lease right-of-use assets | 2,144 | 2,522 |
| Deposits and other long-term assets | 614 | 577 |
| Goodwill | 10,672 | 10,672 |
| Intangible assets, net | 46,540 | 46,562 |
| TOTAL ASSETS | $113,218 | $101,019 |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable and accrued liabilities | $5,437 | $6,270 |
| Operating lease liabilities, current portion | 1,097 | 830 |
| Finance lease liabilities, current portion | 55 | 52 |
| Deferred revenues, current portion | 7,388 | 10,808 |
| Total current liabilities | 13,977 | 17,960 |
| LONG-TERM LIABILITIES | ||
| Deferred tax liability | 273 | 273 |
| Deferred revenues, net of current portion | 14,433 | 18,693 |
| Operating lease liabilities, net of current portion | 1,295 | 1,979 |
| Finance lease liabilities, net of current portion | 67 | 91 |
| Warrant liabilities | 6,161 | — |
| TOTAL LIABILITIES | 36,206 | 38,996 |
| Commitments and contingencies (Note 13) | ||
| SHAREHOLDERS’ EQUITY | ||
| Preferred shares, no par value, 2,000 shares authorized; none issued and outstanding as of December 31, 2024 and 2023 | — | — |
| Common shares, no par value, 450,000 shares authorized as of December 31, 2024 and 2023; 220,416 and 174,987 shares issued and outstanding as of December 31, 2024 and 2023, respectively | 484,722 | 451,343 |
| Accumulated other comprehensive loss | (2,876) | (3,068) |
| Accumulated deficit | (403,465) | (384,856) |
| Lineage's shareholders’ equity | 78,381 | 63,419 |
| Noncontrolling deficit | (1,369) | (1,396) |
| Total shareholders’ equity | 77,012 | 62,023 |
| TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $113,218 | $101,019 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.